中成药
中成藥
중성약
CHINESE TRADITIONAL PATENT MEDICINE
2010年
3期
379-382
,共4页
聚类分析%多药耐药%HL60/HT
聚類分析%多藥耐藥%HL60/HT
취류분석%다약내약%HL60/HT
cluster analysis%multidrug resistance%HL60/HT cells
目的:对具有耐药逆转作用的数种中药成分进行聚类分析.方法:MTT比色法测定补骨脂素、补骨脂甲素、姜黄素、槲皮素、贝母碱、异补骨脂定、补骨脂酚、大黄酸八种中药成分HL60/HT细胞的增殖抑制作用,流式细胞仪测定细胞内化疗药物HT荧光强度及细胞P糖蛋白表达;测定得到的相关数据,通过聚类分析方法进行药物分组.结果:8种药物的逆转倍数在6.2~12.5之间,HL60/HT细胞中HT浓度在9.6~25.6之间,HL60/HT细胞P-gp表达率在29.3~50.1之间.结论:基于4种实验指标呵将八种药物按相似性聚类分成3组:补骨脂素、姜黄素、槲皮素3种成分为第一组,补骨脂甲素、贝母碱、异补骨脂定、大黄酸四种成分为第2组,补骨脂酚为第3组.
目的:對具有耐藥逆轉作用的數種中藥成分進行聚類分析.方法:MTT比色法測定補骨脂素、補骨脂甲素、薑黃素、槲皮素、貝母堿、異補骨脂定、補骨脂酚、大黃痠八種中藥成分HL60/HT細胞的增殖抑製作用,流式細胞儀測定細胞內化療藥物HT熒光彊度及細胞P糖蛋白錶達;測定得到的相關數據,通過聚類分析方法進行藥物分組.結果:8種藥物的逆轉倍數在6.2~12.5之間,HL60/HT細胞中HT濃度在9.6~25.6之間,HL60/HT細胞P-gp錶達率在29.3~50.1之間.結論:基于4種實驗指標呵將八種藥物按相似性聚類分成3組:補骨脂素、薑黃素、槲皮素3種成分為第一組,補骨脂甲素、貝母堿、異補骨脂定、大黃痠四種成分為第2組,補骨脂酚為第3組.
목적:대구유내약역전작용적수충중약성분진행취류분석.방법:MTT비색법측정보골지소、보골지갑소、강황소、곡피소、패모감、이보골지정、보골지분、대황산팔충중약성분HL60/HT세포적증식억제작용,류식세포의측정세포내화료약물HT형광강도급세포P당단백표체;측정득도적상관수거,통과취류분석방법진행약물분조.결과:8충약물적역전배수재6.2~12.5지간,HL60/HT세포중HT농도재9.6~25.6지간,HL60/HT세포P-gp표체솔재29.3~50.1지간.결론:기우4충실험지표가장팔충약물안상사성취류분성3조:보골지소、강황소、곡피소3충성분위제일조,보골지갑소、패모감、이보골지정、대황산사충성분위제2조,보골지분위제3조.
AIM:To do cluster analysis on the herb active ingredients with reversal activity of multi-drug resistance in HL60/HT cells.METHODS:HL60/HT cell was used to check the inhibitory effect of Psoralen,psoralen-A,curcumin,quercetin,psoralidin,isopsoralidin,psoralen phenol,Rhein on cell proliferation by MTT assay.Flow cytometry was used to measure HL fluorescence index and the expression of P-glucose protein.On the basis of the experimental data,herbs were classified as different groups by cluster analysis.RESULTS:Reversion rate,HT concentration and P-gp expression of HL60/HT fell within the range of 6.2 to 12.5,9.6 to 25.6,and 29.3 to 50.1,respectively.CONCLUSION:According to cluster similarity,8 herbal ingredients could be divided into three groups,psoralen,curcumin and quercetin were in the first group.Psoralen-A,psoralidin,isopsoralidin and rhein were in the second group,psoralen phenol was in the third group.